{
"id": "https://doi.org/10.6084/m9.figshare.14569128",
"doi": "10.6084/M9.FIGSHARE.14569128",
"url": "https://tandf.figshare.com/articles/journal_contribution/Risk_of_Ophthalmic_Adverse_Events_in_Patients_Treated_with_Immune_Checkpoint_Inhibitor_Regimens_A_Systematic_Review_and_Meta-analysis/14569128",
"types": {
"ris": "RPRT",
"bibtex": "article",
"citeproc": "article-journal",
"schemaOrg": "ScholarlyArticle",
"resourceType": "Journal contribution",
"resourceTypeGeneral": "Text"
},
"creators": [
{
"name": "Hou, Yan-Li",
"givenName": "Yan-Li",
"familyName": "Hou"
},
{
"name": "Wang, Di-Ya",
"givenName": "Di-Ya",
"familyName": "Wang"
},
{
"name": "Hu, Jie-Xuan",
"givenName": "Jie-Xuan",
"familyName": "Hu"
},
{
"name": "Tian, Ru-Yue",
"givenName": "Ru-Yue",
"familyName": "Tian"
},
{
"name": "Wang, Wei",
"givenName": "Wei",
"familyName": "Wang"
},
{
"name": "Su, Qiang",
"givenName": "Qiang",
"familyName": "Su"
},
{
"name": "Li, Hongyang",
"givenName": "Hongyang",
"familyName": "Li"
},
{
"name": "Wang, Yan-Ling",
"givenName": "Yan-Ling",
"familyName": "Wang"
}
],
"titles": [
{
"title": "Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis"
}
],
"publisher": {
"name": "Taylor & Francis"
},
"container": {},
"subjects": [
{
"subject": "Medicine"
},
{
"subject": "Physiology"
},
{
"subject": "FOS: Biological sciences",
"schemeUri": "http://www.oecd.org/science/inno/38235147.pdf",
"subjectScheme": "Fields of Science and Technology (FOS)"
},
{
"subject": "Pharmacology"
},
{
"subject": "Immunology"
},
{
"subject": "FOS: Clinical medicine",
"schemeUri": "http://www.oecd.org/science/inno/38235147.pdf",
"subjectScheme": "Fields of Science and Technology (FOS)"
},
{
"subject": "Marine Biology"
},
{
"subject": "Cancer"
}
],
"contributors": [],
"dates": [
{
"date": "2021-05-10",
"dateType": "Created"
},
{
"date": "2023-06-05",
"dateType": "Updated"
},
{
"date": "2021",
"dateType": "Issued"
}
],
"publicationYear": 2021,
"identifiers": [],
"sizes": [
"4152962 Bytes"
],
"formats": [],
"rightsList": [
{
"rights": "Creative Commons Attribution 4.0 International",
"rightsUri": "https://creativecommons.org/licenses/by/4.0/legalcode",
"schemeUri": "https://spdx.org/licenses/",
"rightsIdentifier": "cc-by-4.0",
"rightsIdentifierScheme": "SPDX"
}
],
"descriptions": [
{
"description": "Immune checkpoint inhibitors (ICIs) -induced adverse events (AEs) have been reported affecting almost all human organs. However, studies about ocular AEs are few. A meta-analysis was performed to evaluate the risks of ICI-related ophthalmic AEs compare to chemotherapy. Methods: Eligible studies were selected from phase II/III randomized controlled trials investigating ICIs. The data were analyzed by R software and Stata. Odds ratio of treatment-related AE (trAEs) and nonspecific ophthalmic trAEs (NS-trAEs) were lower for PD-1/PD-L1 inhibitors than chemotherapy (OR 0.44, p < .05; OR 0.28, p < .001; OR 0.18, p < . 05; OR: 0.18, p < .001respectively). Compared with monotherapy, PD-1 plus CTLA-4 inhibitors increased the risks of immune-related AEs (irAEs) (OR 4.52, p < .01); ICIs plus chemotherapy increased the risks of trAEs and irAEs (OR 2.82, p < .001; OR 3.63, p < .05 respectively). PD-L1/PD-1 inhibitors had lower risks of trAEs and NS-trAEs than chemotherapy; Compared with monotherapy, combination therapy had higher risks of ophthalmic trAEs and irAEs. PD-1: programmed cell death protein 1; PD-L1: programmed cell death protein ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; ICI: immune checkpoint inhibitor; AE: adverse event; trAE: treatment-related adverse event;irAE: immune-related adverse events; NS-trAE: nonspecific ophthalmic treatment-related adverse event; RCT: randomized controlled trials; PFS: progression-free survival; OS: overall survival; ORR: objective response rate; MM: melanoma; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; HNSCC: head-neck squamous cell carcinoma; PICOL: patient, intervention, comparison, and outcome; Versus: VS; Chem: chemotherapy; 95%CI: 95% confidence interval; FEM: fixed-effects model; REM: random-effects model; NA: not applicable; MeSH: medical subject heading",
"descriptionType": "Abstract"
}
],
"geoLocations": [],
"fundingReferences": [],
"relatedIdentifiers": [
{
"relationType": "IsSupplementTo",
"relatedIdentifier": "10.1080/09273948.2021.1890133",
"relatedIdentifierType": "DOI"
}
],
"relatedItems": [],
"schemaVersion": "http://datacite.org/schema/kernel-4",
"providerId": "otjm",
"clientId": "figshare.ars",
"agency": "datacite",
"state": "findable"
}